CoChat

Once-monthly maridebart cafraglutide for the treatment of obesity—a phase 2 trial

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Maridebart cafraglutide (known as MariTide) is a long-acting peptide-antibody conjugate that combines glucagon-like peptide-1 receptor agonism and glucose-dependent insulinotropic polypeptide receptor antagonism and that is intended for the treatment of obesity. METHODS: We conducted a phase 2, double-blind, randomized, placebo-controlled, dose-ranging trial that included 11 groups as two cohorts. Participants with obesity (obesity cohort) were randomly assigned in a 3:3:3:2:2:2:3 ratio to receive maridebart cafraglutide subcutaneously at a dose of 140, 280, or 420 mg every 4 weeks without dose escalation; 420 mg every 8 weeks without dose escalation; 420 mg every 4 weeks with 4-week dose escalation; 420 mg every 4 weeks with 12-week dose escalation; or placebo. Participants with obesity with type 2 diabetes (obesity-diabetes cohort) were randomly assigned in a 1:1:1:1 ratio to receive maridebart cafraglutide at a dose of 140, 280, or 420 mg every 4 weeks (all without dose escalation) or placebo. The primary end point was the percent change in body weight from baseline to week 52. RESULTS: We enrolled 592 participants. In the obesity cohort (465 participants; female sex, 63%; mean age, 47.9 years; mean body-mass index [BMI, the weight in kilograms divided by the square of the height in meters], 37.9), the mean percent change in body weight from baseline to week 52 on the basis of the treatment policy estimand (intention-to-treat approach) ranged from -12.3% (95% confidence interval [CI], -15.0 to -9.7) to -16.2% (95% CI, -18.9 to -13.5) with maridebart cafraglutide, as compared with -2.5% (95% CI, -4.2 to -0.7) with placebo. In the obesity-diabetes cohort (127 participants; female sex, 42%; mean age, 55.1 years; mean BMI, 36.5), the mean percent change in body weight from baseline to week 52 on the basis of the treatment policy estimand ranged from -8.4% (95% CI, -11.0 to -5.7) to -12.3% (95% CI, -15.3 to -9.2) with maridebart cafraglutide, as compared with -1.7% (95% CI, -2.9 to -0.6) with placebo. The mean change in the glycated hemoglobin level on the basis of the treatment policy estimand in this cohort was -1.2 to -1.6 percentage points in the maridebart cafraglutide groups and 0.1 percentage points in the placebo group. Gastrointestinal adverse events were common with maridebart cafraglutide, although less frequent with dose escalation and a lower starting dose. No unexpected safety signals emerged. CONCLUSIONS: In this phase 2 trial, once-monthly maridebart cafraglutide resulted in substantial weight reduction in participants with obesity with or without type 2 diabetes. (Funded by Amgen; ClinicalTrials.gov number, NCT05669599.).

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa2504214

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 34 references

Cited by

See all 110

Metadata

Authors
Jastreboff, A. M., Ryan, D. H., Bays, H. E., Ebeling, P. R., Mackowski, M. G., Philipose, N., Ross, L., Liu, Y., Burns, C. E., Abbasi, S. A., & Pannacciulli, N.
Affiliations
  • Yale University (US)
  • Pennington Biomedical Research Center (US)
  • University of Louisville (US)
  • Monash Health (AU)
  • Amgen (United States) (US)
Venue
New England Journal of Medicine
Published
2025-09-04
Volume
393
Issue
9
Pages
843-857
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4411542117
Cited by
110
References
34
Citations by year
2026: 89 · 2025: 21
FWCI
61.79
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
Amgen
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
obesity, type 2 diabetes, GLP-1 receptor agonists, GIP receptor antagonist, weight loss, dose escalation, once-monthly dosing, dose-ranging, treatment policy estimand, weight regain after weight loss, adverse events
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Adult, Aged, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Obesity, Receptors, Gastrointestinal Hormone, Weight Loss, Body Mass Index, Immunoconjugates, Anti-Obesity Agents, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Once-monthly maridebart cafraglutide for the treatment of obesity—a phase 2 trial. https://app.cochat.ai/papers/10.1056/nejmoa2504214
The paper
Jastreboff, A. M., Ryan, D. H., Bays, H. E., Ebeling, P. R., Mackowski, M. G., Philipose, N., Ross, L., Liu, Y., Burns, C. E., Abbasi, S. A., & Pannacciulli, N. (2025). Once-monthly maridebart cafraglutide for the treatment of obesity—a phase 2 trial. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2504214

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.